ASH 2024: Autolus CEO Christian Itin talks about the approval of of the CAR-T Aucatzyl, as well as the company's development pipeline (including autoimmune)

blonca9
Dec 7, 2024
1 min read

He discusses Autolus' 'fast off' approach to CAR-T and why he believes the safety benefits led to no REMS requirement for Aucatzyl. Plus, ASH presentations, and how Autolus is the only company using a commercially approved CD19 construct in clinical trials for autoimmune disease.

Recent Posts

See All

On its 10-year anniversary, Arcus Biosciences is taking its 4th molecule into pivotal studies. Co-Founder & CEO Terry Rosen talks HIF-2⍺, TIGIT, and CD73

Siren Biotechnology is using an online platform to raise up to $5 million from the public in a "community round" - it might be a new avenue of funding for biotech companies

Theravance Biopharma has a key pivotal trial readout scheduled for late '25 / early '26 in symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA)

ASH 2024: Autolus CEO Christian Itin talks about the approval of of the CAR-T Aucatzyl, as well as the company's development pipeline (including autoimmune)

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight